April 24, 2025 — HeartBeam, Inc. recently announced a strategic collaboration with AccurKardia to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia’s FDA-cleared ECG analysis software, AccurECG, available on HeartBeam’s devices.*
“This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring,” said Robert Eno, Chief Executive Officer of HeartBeam. “AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.”
Adding AccurKardia’s FDA-cleared, device-agnostic automated ECG interpretation platform to HeartBeam’s device will enhance HeartBeam’s subsequent commercial offering for arrhythmia assessment by enabling patients and physicians to get an automated rhythm assessment which will facilitate a quicker diagnosis and faster access to clinical care when needed. The strategic collaboration is expected to expedite HeartBeam’s product development efforts, reducing both costs and timelines.
“We believe combining AccurKardia’s device-agnostic, FDA-cleared automated ECG analytics with HeartBeam’s novel credit card-sized device will be a true game-changer that empowers patients to take charge of their cardiac health, wherever they are. By uniting our strengths, we’re creating a best-in-class platform that transforms how cardiac arrhythmia conditions are monitored and detected,” said Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia. “Putting clinical-grade ECG insights directly into a patient’s pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the United States.”
*The combined HeartBeam–AccurKardia solution is under development and has not been cleared by the U.S. Food and Drug Administration.
August 15, 2024 
